The use of potassium-competitive acid blockers in the management of foregut disease

View at publisher Summarise with VIRAT
Authors: Megan B. Ghai, Joshua A. Sloan
Cited by: 0
References: 34

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

PURPOSE OF REVIEW: The purpose of this review is to explore the current clinical evidence evaluating the use of potassium-competitive acid blockers (PCABs) in the management of foregut diseases. RECENT FINDINGS: PCABs have been shown to have clinical superiority over proton pump inhibitors in the management of H. pylori and Los Angeles grade C/D erosive esophagitis. PCABs also are approved for use in nonerosive reflux disease, and data suggest a possible use in peptic ulcer disease. SUMMARY: There is utility of PCABs in the management of multiple foregut diseases. More data are required to understand the utility of PCABs in the management of Barett's esophagus and eosinophilic esophagitis.

Fields of Study & Subjects

Gastroesophageal reflux and treatments Helicobacter pylori-related gastroenterology studies Gastrointestinal Bleeding Diagnosis and Treatment

Publication details

Journal / source
Current Opinion in Gastroenterology
Volume
42
Issue
4
Pages
298–303
Publication date
30 March 2026
Language
EN